Regulatory T-cell therapy in Crohn's disease: challenges and advances.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 31980447.
- Also identified by DOI 10.1136/gutjnl-2019-319850 and PMC identifier 7229901.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
The prevalence of IBD is rising in the Western world. Despite an increasing repertoire of therapeutic targets, a significant proportion of patients suffer chronic morbidity. Studies in mice and humans have highlighted the critical role of regulatory T cells in immune homeostasis, with defects in number and suppressive function of regulatory T cells seen in patients with Crohn's disease. We review the function of regulatory T cells and the pathways by which they exert immune tolerance in the intestinal mucosa. We explore the principles and challenges of manufacturing a cell therapy, and discuss clinical trial evidence to date for their safety and efficacy in human disease, with particular focus on the development of a regulatory T-cell therapy for Crohn's disease.
Medical subject headings
- Cell- and Tissue-Based Therapy
- Crohn Disease
- Intestinal Mucosa
- T-Lymphocytes, Regulatory